Eicosapentaenoic Acid Monoglycerides for Brain Fog

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of Eicosapentaenoic Acid Monoglycerides (MAG-EPA) on cognitive health, particularly focusing on symptoms of brain fog, which have been reported by many individuals post-COVID-19. The study is divided into two phases: the first phase involves a single-arm treatment with eight participants, while the second phase will include 40 participants randomized into treatment and placebo groups. Participants will complete a Brain Fog Scale questionnaire to assess their cognitive health before and during the treatment period. The goal is to determine if MAG-EPA can improve cognitive function in those experiencing brain fog.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Participant between 19 and 55 years of age.
2. Participant who reports having mental fatigue and/or frequent memory loss and/or difficulty concentrating and/or inattention, confusion and/or a feeling of decreased cognitive acuity for at least 28 days at the time of selection.
3. Participant who obtains a mean score on the BFS screening questionnaires (BFS1 and BFS2) total of at least 30 and/OR who obtains the following minimum score on at least one of the three factors: Factor 1 of at least 15 and/or Factor 2 of at least 15 and/or Factor 3 of at least 12.
4. Available for the entire duration of the study and willing to participate based on the information provided in the ICF duly read and signed by the latter.
5. Absence of intellectual problems likely to limit the validity of consent to participate in the study or the compliance with protocol requirements, ability to cooperate adequately, ability to understand and observe the instructions of the research staff.
6. Participant having no difficulty in swallowing tablets, capsules or gelcaps.

Exclusion Criteria:

1. Known allergy or intolerance to fish or history of allergic reactions attributable to fish, or to a compound similar to fish oil.
2. Participant who has used omega-3 supplements in the 30 days preceding day 1 of the study.
3. Pregnant or breastfeeding woman as declared by the latter.
4. Presence of dependence on drugs of abuse or alcohol (˃ 3 units of alcohol per day, acute or chronic excessive consumption).
5. Participant included in another clinical study and who is receiving an investigational product or other research treatment.

Where it's running

• Institut de recherche clinique du littoral (IRCL)
  Maria, Quebec, Canada Recruiting
• Institut de recherche clinique du littoral (IRCL)
  Rimouski, Quebec, Canada Recruiting

Study contacts

• Study coordinator: Samuel Fortin, Investigator, Ph.D
• Email: sfortin@scfpharma.com
• Phone: 1-418-750-8590

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Omega-3 supplement to boost DHA and EPA levels in the blood

  This 12-week study tests whether the Omega Active supplement raises blood DHA and EPA levels in healthy adults aged 18–65 who have omega-3 needs.

  Recruiting Revive Active · Las Vegas, Nevada · NCT07753174

• Cognitive rehabilitation for ME/CFS brain fog

  Researchers are testing two cognitive rehabilitation approaches to see which helps adults with ME/CFS and brain fog better manage thinking and daily tasks.

  Recruiting University of Alabama at Birmingham · Birmingham, Alabama · NCT07523113

• Stasis supplement to reduce stimulant medication side effects

  We will test whether taking Stasis daytime and nighttime supplements for three months reduces sleep problems, irritability, anxiety, and brain fog in adults on stimulant medication for ADHD.

  Recruiting Outliers, Inc. · Las Vegas, Nevada · NCT07380412

• Focused ultrasound to improve thinking in post‑COVID brain fog

  This project will see if short, targeted pulses of ultrasound to a specific brain area can improve thinking, attention, and other cognitive symptoms in people with persistent brain fog after COVID‑19.

  Recruiting at 2 sites Xuanwu Hospital, Beijing · Beijing, Beijing Municipality and 1 other locations · NCT07154199

• A program to reduce dementia risk in older adults in care facilities

  This study tests a new program aimed at helping older adults in care facilities lower their risk of dementia by improving their social and mental activities.

  Recruiting University of Coimbra · Coimbra, Portugal · NCT06922071

• PotenziaMente: a tablet-based cognitive training program for healthy older adults

  A tablet-based cognitive training program is being tested to see if it can improve executive function in healthy adults ages 65–75, comparing home use to supervised tablet sessions.

  Recruiting Università degli Studi di Trento · Rovereto, Trento · NCT07639203

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.